Therapeutic angiogenesis using bone marro w-derived mononuclear cells implantation for critical limb ischemia (Therapeutic angiogenesis for critical limb ischemia) - Therapeutic angiogenesis using bone marro w-derived mononuclear cells implantation for critical limb ischemia (Therapeutic angiogenesis for critical limb ischemia)

Matoba Satoaki0 个研究点目标入组 50 人开始时间: 2020年3月26日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•We enroll patients included all of the inclusion criteria.
•1) Patients who are over 20 years old and under 80 years old when obtaining written consent.
•2) Any gender is acceptable.
•3) Fontaine III-severe severe ischemic limb (occlusive arteriosclerosis, Buerger's disease, vasculitis due to collagen disease).
•4) Patients who have been confirmed that there is no recovery after applying the standard treatment listed in the insurance, or who are judged to have no indication for revascularization by vascular surgeons and cardiologists, and who will be forced to have amputation in the future. (Includes patients with the possibility of small amputation.) (*)
•5) Regarding the benefits / disadvantages arising from receiving a cell transplant and the benefits / disadvantages arising from not receiving a cell transplant, the patient's will and / or family's understanding and consent will be fully explained in the consent explanation document. Patients who have obtained written consent to participate in the study.
•(*) Standard treatment listed in insurance '' refers to drug therapy such as blood flow improving drugs and anti-inflammatory analgesics, exercise therapy, sympathetic ganglion block, and revascularization such as percutaneous angioplasty and bypass.

•1) Even if the disease and the surgical procedure are appropriate, informed consent cannot be obtained from the patient, or emotional consideration is required for the patient's family and it is difficult to adapt.
•2) Life expectancy is less than one year due to other complications.
•3) When a malignant tumor is diagnosed.
•4) If you have ischemic heart disease and have not been revascularized.
•5) If you have severe diabetic retinopathy and have not been treated.
•6) If you have a serious infection.
•7) When severe liver dysfunction or renal dysfunction (excluding maintenance dialysis patients) exists.
•8) When there are severe blood disorders such as leucopenia and thrombocytopenia and severe anemia requiring blood transfusion.
•9) Pregnant and possibly pregnant or breastfeeding.
•10) Those who participated in clinical trials or clinical trials for pharmaceuticals or medical devices at the same time as this trial or within 30 days before enrollment in this trial.
•11) Other serious acute / chronic medical / mental conditions or laboratory abnormalities that may increase the risk of study participation or may affect the interpretation of study results .
•12) In addition, when the person in charge of the implementation or the investigator determines that it is inappropriate to participate in this study.

发起方

Matoba Satoaki